Non-specific PAF binding to embryonal F9 cells and prostacyclin synthesis in human umbilical vein endothelial cells.
Our data suggest non-specific Paf binding to intact embryonal F9 cells. Non-specific Paf binding might have some physiological relevance when Paf metabolites interfere with prostacyclin synthesis, for example, in umbilical vein endothelial cells.
Korth
R M
RM
Forschung in der Allgemeinmedizin FIDA, München, Germany.
D015121:6-Ketoprostaglandin F1 alpha / Q000096:biosynthesis; D000818:Animals; D001381:Azepines / Q000494:pharmacology; D018236:Carcinoma, Embryonal / Q000378:metabolism; D002460:Cell Line; D004622:Embryo, Mammalian / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D011464:Epoprostenol / Q000096:biosynthesis*; D006801:Humans; D051379:Mice; D009373:Neoplasms, Germ Cell and Embryonal / Q000378:metabolism; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors / Q000378:metabolism*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D014230:Triazoles / Q000494:pharmacology; D014471:Umbilical Veins / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*
D001381:Azepines; D010972:Platelet Activating Factor; D010975:Platelet Aggregation Inhibitors; D014230:Triazoles; C052518:WEB 2086; D015121:6-Ketoprostaglandin F1 alpha; D011464:Epoprostenol